share_log

CVS Health | 10-Q: Q3 2024 Earnings Report

CVS Health | 10-Q: Q3 2024 Earnings Report

西維斯健康 | 10-Q:2024財年三季報
美股SEC公告 ·  2024/11/06 20:37

牛牛AI助理已提取核心訊息

CVS Health reported a sharp decline in Q3 2024 earnings as net income plummeted 96% to $87 million from $2.26 billion a year ago, while revenues rose 6.3% to $95.4 billion. The company recorded $1.2 billion in restructuring charges and established premium deficiency reserves of approximately $1.1 billion primarily related to Medicare and individual exchange products. The medical benefit ratio surged to 95.2% from 85.7% due to increased utilization.The company announced plans to close 271 retail stores in 2025 as part of an enterprise-wide restructuring program aimed at streamlining operations and reducing costs. The restructuring charges included a $607 million store impairment charge, $293 million in corporate workforce optimization costs, and $269 million in other asset impairments. Total revenues were driven by growth in Health Care Benefits and Pharmacy & Consumer Wellness segments.Pharmacy & Consumer Wellness segment saw same-store sales increase 19.5% year-over-year, with prescription volume up 9.1%. The Health Services segment's adjusted operating income rose 17.4% to $2.2 billion despite revenue declining 5.9% to $44.1 billion. The company maintained its retail pharmacy network while expanding its healthcare delivery capabilities through Oak Street Health and Signify Health acquisitions.
CVS Health reported a sharp decline in Q3 2024 earnings as net income plummeted 96% to $87 million from $2.26 billion a year ago, while revenues rose 6.3% to $95.4 billion. The company recorded $1.2 billion in restructuring charges and established premium deficiency reserves of approximately $1.1 billion primarily related to Medicare and individual exchange products. The medical benefit ratio surged to 95.2% from 85.7% due to increased utilization.The company announced plans to close 271 retail stores in 2025 as part of an enterprise-wide restructuring program aimed at streamlining operations and reducing costs. The restructuring charges included a $607 million store impairment charge, $293 million in corporate workforce optimization costs, and $269 million in other asset impairments. Total revenues were driven by growth in Health Care Benefits and Pharmacy & Consumer Wellness segments.Pharmacy & Consumer Wellness segment saw same-store sales increase 19.5% year-over-year, with prescription volume up 9.1%. The Health Services segment's adjusted operating income rose 17.4% to $2.2 billion despite revenue declining 5.9% to $44.1 billion. The company maintained its retail pharmacy network while expanding its healthcare delivery capabilities through Oak Street Health and Signify Health acquisitions.
西維斯健康在2024年第三季度報告了盈利大幅下滑,凈利潤暴跌96%,從去年22.6億降至8700萬,同時營業收入增長6.3%,達954億。公司記錄了12億的重組費用,並設立了大約11億的保費不足準備金,主要與醫療保險和個人交易所產品相關。由於使用量增加,醫療福利比率從85.7%飆升至95.2%。公司宣佈計劃在2025年關閉271家零售店,作爲一項旨在簡化運營和降低成本的企業範圍重組計劃的一部分。重組費用包括60700萬的門店減值費用、29300萬的企業員工優化成本和26900萬的其他資產減值。總營業收入由醫療保健福利和藥房及消費健康部門的增長推動。藥房及消費健康部門的同店銷售同比增長19.5%,處方成交量增長9.1%。儘管營業收入下降5.9%至441億,健康服務部門的調整後營業收入仍上升17.4%,達22億。公司保持了其零售藥房網絡,同時通過收購Oak Street Health和Signify Health擴展其醫療服務能力。
西維斯健康在2024年第三季度報告了盈利大幅下滑,凈利潤暴跌96%,從去年22.6億降至8700萬,同時營業收入增長6.3%,達954億。公司記錄了12億的重組費用,並設立了大約11億的保費不足準備金,主要與醫療保險和個人交易所產品相關。由於使用量增加,醫療福利比率從85.7%飆升至95.2%。公司宣佈計劃在2025年關閉271家零售店,作爲一項旨在簡化運營和降低成本的企業範圍重組計劃的一部分。重組費用包括60700萬的門店減值費用、29300萬的企業員工優化成本和26900萬的其他資產減值。總營業收入由醫療保健福利和藥房及消費健康部門的增長推動。藥房及消費健康部門的同店銷售同比增長19.5%,處方成交量增長9.1%。儘管營業收入下降5.9%至441億,健康服務部門的調整後營業收入仍上升17.4%,達22億。公司保持了其零售藥房網絡,同時通過收購Oak Street Health和Signify Health擴展其醫療服務能力。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。